ABT Stock Analysis & Forecast (2026)

Abbott Laboratories Healthcare Medical Devices
$96.81
Current Price
78%
Buy
View Plans
Data refreshed: April 20, 2026

Key Financial Metrics

Market Cap
$168.23B
P/E Ratio (TTM)
27.1x
P/E Forward
16.0x
Revenue Growth
7.8%
Gross Margin
56.5%
Net Margin
13.9%
Debt/Equity
0.27

AI Analysis Summary

Abbott Laboratories (ABT) is a Healthcare company in the Medical Devices industry with a 78% Buy Score. Key strengths include Gross Margin (56.5%), Net Margin (13.9%), Debt/Equity (0.27). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Moderate Gross Margin: Excellent Net Margin: Good Debt/Equity: Low Risk

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

ABT Fundamental Analysis Report
PDF Report Preview
78%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free ABT Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes ABT fundamentals to generate buy/sell signals and Strong Buy Scores.

Why ABT Has a 78% Score

Our AI evaluates Abbott Laboratories's fundamentals across multiple dimensions. Here is what is driving the current Buy rating:

Recent Catalysts for ABT

Key developments and data points that may impact Abbott Laboratories's trajectory:

Earnings declined -19.7% — watch for stabilization in coming quarters.
Wall Street consensus target is $120.00 (+24.0% from current price), based on 25 analyst estimates.
Analyst consensus recommendation: Buy.
Institutional ownership at 82.0% — strong smart-money backing.
Dividend yield of 2.60% provides income while you wait for capital appreciation.

ABT vs. Peers

How Abbott Laboratories stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
ABT $96.81 $168.23B 27.1x 7.8% 13.9%
JNJ $234.18 $564.35B 21.2x 9.9% 21.8%
UNH $324.63 $294.66B 24.5x 12.3% 2.7% 12.5%
PFE $27.56 $156.77B 20.3x -1.2% 12.4% 8.9%
MRK $119.07 $294.39B 16.4x 5.0% 28.1% 36.9%

Main Risks for ABT Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Abbott Laboratories:

Competitive pressures in the Healthcare sector.
Macroeconomic headwinds including interest rate changes and consumer spending shifts.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

ABT Balance Sheet & Cash Flow

A snapshot of Abbott Laboratories's financial health based on the most recent filings:

Total Cash
$8.94B
Total Debt
$14.14B
EBITDA
$12.15B
Operating Margin
16.5%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

ABT Valuation Snapshot

Trailing P/E
27.1x
Growth premium
Forward P/E
16.0x
Earnings growth expected
Price / Book
3.2x
Premium
PEG Ratio
1.40
Fairly valued
Analyst Target (Mean)
$120.00
Range: $108 – $143
Dividend Yield
2.60%
5Y avg: 1.77%
52-Week Price Range — ABT is trading at 6% of its range
$93.92 (52W Low) $139.06 (52W High)

Is ABT a Buy Right Now?

Based on our AI-powered fundamental analysis, ABT has a Strong Buy Score of 78%, earning a "Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Strong Buy Signal

Abbott Laboratories demonstrates robust fundamentals across multiple categories. Key strengths include Gross Margin (56.5%) and Net Margin (13.9%). The stock shows characteristics typically associated with outperformers.

ABT AI Buy & Sell Signals Explained

Our AI analyzes Abbott Laboratories's financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 78% score:

  • Revenue Growth: 7.8% year-over-year (positive)
  • Gross Margin: 56.5% (strong pricing power)
  • Net Margin: 13.9% (profitable)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for ABT on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With ABT currently trading at $96.81, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when ABT reaches key technical levels.

Earnings & Revenue Outlook

Abbott Laboratories operates in the Healthcare sector, specifically in Medical Devices. Understanding earnings trends is crucial for forecasting ABT's trajectory.

Current revenue growth of 7.8% exceeds the average company.

Visit our Earnings Calendar to track upcoming ABT earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

ABT Stock Forecast (Next 3–12 Months)

Our AI projects ABT's trajectory based on current fundamentals and historical patterns. With a 78% Strong Buy Score, here's what the data suggests:

Bullish Outlook: Abbott Laboratories shows strong fundamental momentum. Stocks with similar profiles have historically outperformed over 12-month periods.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if ABT is fairly priced. Here's the current snapshot:

  • Market Capitalization: $168.23B
  • P/E Ratio (TTM): 27.1x (growth premium)
  • Forward P/E: 16.0x (based on analyst estimates)
  • Debt/Equity: 0.27 (conservative balance sheet)

Our AI weighs these metrics against growth rates and margin quality to determine if ABT offers compelling risk-adjusted returns at current prices.

Bull Case for ABT

Here's why investors are bullish on Abbott Laboratories:

  • Gross Margin (56.5%)
  • Net Margin (13.9%)
  • Debt/Equity (0.27)

With a 78% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.

Bear Case & Risks for ABT

Every investment carries risk. Here are potential concerns for ABT investors:

  • Competitive pressures in Healthcare
  • Macroeconomic sensitivity and interest rate exposure
  • Execution risk on growth initiatives
  • Valuation compression if growth slows

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

ABT Summary: Abbott Laboratories earns a 78% Buy Score based on AI analysis of fundamental data. Trading at $96.81 with a $168.23B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.

Bull Case: Gross Margin (56.5%), Net Margin (13.9%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free ABT PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this ABT analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like ABT.

What Are Demand Zones?

Find key support and resistance levels for ABT and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for ABT

Demand Zone Analyzer ABT Live Chart Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

Frequently Asked Questions about ABT

Is ABT a good buy right now?
ABT currently has a Strong Buy Score of 78% (Buy). Based on AI analysis of fundamentals, ABT shows strong buy signals with solid revenue growth, margins, and return metrics. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the ABT stock forecast for 2026?
Our AI forecasts ABT based on current fundamentals: revenue growth of 7.8%, net margin of 13.9%, and P/E of 27.1x. The 78% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for ABT?
View real-time ABT demand zones (support) and supply zones (resistance) on our Demand Zones page. With ABT currently at $96.81, you can see how close the stock is to key technical levels. Subscribe to get alerts when ABT approaches these zones.
How do ABT fundamentals compare to peers?
Abbott Laboratories operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 56.5%, Debt/Equity 0.27. The 78% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the ABT analysis PDF report free?
Yes! Your first ABT fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Abbott Laboratories's market cap and P/E ratio?
Abbott Laboratories (ABT) has a market cap of $168.23B and a trailing P/E ratio of 27.1x (forward P/E: 16.0x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This ABT analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.